Tenax Therapeutics, Inc. TENX
Regular-session close
After hours · Nov 20, 6:29 PM ET
- YTD
- -89.75%
- 1 year
- -83.77%
5D -0.21 (-13.13%)
- Market cap
- 56.92M
- EPS (ttm)
- -1.39
- Shares out
- 3.41M
- Forward P/E
- -1.06
- YTD return
- -89.75%
- 1-year return
- -83.77%
- 50-day average
- 4.96
- 200-day average
- 3.94
- Volume
- 2.28M
- Avg volume
- 3.18M
- Open
- 1.32
- Previous close
- 1.39
- Day's range
- 1.24 – 1.35
- 52-week range
- 1.24 – 19.40
- Beta
- 2.15
- Price target
- 16.30 (+1204.0%)
Key statistics
- Enterprise value
- 7.73M
- Price / book
- 0.20
- Free cash flow
- -7.55M
- Total cash
- 9.38M
- Total debt
- 278.80K
- Return on equity
- -113.79%
- Short % of float
- 4.10%
Fundamental scorecard
6 of 25 checks passed on TENX’s reported financials
6of 25 checks passed
- Value 1 of 5
- Growth 0 of 5
- Profitability 0 of 5
- Financial health 5 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2024 | Sep 1, 2024 | -1.38 | -0.19 | +1.19 | +86.23% |
| Aug 13, 2024 | Jun 1, 2024 | -1.99 | -1.83 | +0.16 | +8.04% |
| May 14, 2024 | Mar 1, 2024 | -2.40 | -3.12 | -0.72 | -30.00% |
| Apr 1, 2024 | Dec 1, 2023 | -8.15 | — | — | — |
| Nov 13, 2023 | Sep 1, 2023 | -7.20 | -6.40 | +0.80 | +11.11% |
| Aug 14, 2023 | Jun 1, 2023 | 0.00 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 24, 2024 | Leerink Partners | init | — | Outperform |
| Feb 20, 2024 | Roth MKM | reit | Buy | Buy |
About Tenax Therapeutics, Inc.
Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- tenaxthera.com
News
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Tenax Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - TENX
What Should Tenax Therapeutics, Inc. Investors Know After 89.77% Stock Drop? The Law Offices of Frank R.
Kaplan Fox Alerts Investors to a Deadline for a Securities Fraud Class Action Lawsuit Against Tenax Therapeutics, Inc. (TENX) on December 28, 2026
ROSEN, A LEADING NATIONAL FIRM, Encourages Tenax Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - TENX
ROSEN, NATIONAL TRIAL COUNSEL, Encourages Tenax Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - TENX
DEADLINE ALERT for Tenax Therapeutics, Inc. (TENX), Everest Group, Ltd. (EG), and Lululemon Athletica, Inc (LULU): The Law Offices of Howard G.
DEADLINE ALERT for UP Fintech Holding Limited (TIGR), Tenax Therapeutics, Inc. (TENX), Everest Group, Ltd. (EG), and Yiren Digital Ltd.
TENAX THERAPEUTICS, INC. SECURITIES FRAUD NOTICE: Berger Montague Informs Tenax Therapeutics, Inc. (TENX) Investors of a Securities Fraud Lawsuit
SHAREHOLDER ALERT: Bronstein Gewirtz & Grossman, LLC Announces Class Action Against Tenax Therapeutics, Inc. (TENX) - Investors Who Suffered Losses Are Encouraged to Contact the Firm
Faruqi & Faruqi, LLP Urges Tenax Therapeutics, Inc. (NASDAQ: TENX) Investors to Seek Counsel Before the December 28, 2026 Lead Plaintiff Deadline in the Securities Class Action
Your note
Sign in to keep a note on TENX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| DAVIDSON MICHAEL H | Director | Purchase | Aug 7, 2024 | 2,881 |
| PROEHL GERALD T | Director | Purchase | Aug 7, 2024 | 1,667 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| BVF Inc. | 9.96% | 339,549 | 1.86M | Sep 29, 2024 |
| Vivo Capital, LLC | 6.11% | 208,333 | 1.14M | Sep 29, 2024 |
| VR Adviser, LLC | 6.11% | 208,333 | 1.14M | Sep 29, 2024 |
| Velan Capital Investment Management LP | 2.44% | 83,333 | 457.50K | Sep 29, 2024 |
| Adage Capital Partners GP L.L.C. | 2.44% | 83,333 | 457.50K | Sep 29, 2024 |
| Vestal Point Capital, LP | 2.44% | 83,333 | 457.50K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Price (T.Rowe) Health Sciences Fund | 0.78% | 26,472 | 145.33K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.30% | 10,217 | 56.09K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.18% | 5,984 | 32.85K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.14% | 4,708 | 25.85K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.07% | 2,326 | 12.77K | Sep 29, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.01% | 364 | 2.00K | Oct 30, 2024 |
